Do the Impossible: Find a Stock with Value and Growth

Courtesy of via Google Images.
Courtesy of via Google Images.

Three noteworthy aspects of the current U.S. economy substantiate a possible detriment to the U.S. dollar. First, America’s deficits have nearly tripled since the 1980s and, second, the manufacturing portion of the Gross Domestic Product (GDP) is down at the moment. Additionally, service industries are achieving little export. Together, these three components could bring about a dangerous dollar dilemma, according to Forbes contributor, Eamonn Fingleton. His article goes on to compare the money markets of the U.S., Europe, and East Asia to analyze what may happen to the dollar. Check out the article HERE to find out Fingleton’s advice on where to invest your dollars to avoid the potential doomsday.

Verizon Could Owe Apple Big Time

Courtesy of via Google Images.
Courtesy of via Google Images.

Back in 2010 when Apple first signed with Verizon to sell iPhones, Verizon committed to selling a certain number of phones each year. However, Verizon seems unable to sell the amount specified and could owe Apple up to $14 billion for the shortfall in sales. With analysts predicting a decline on iPhone sales at the moment, Verizon just may end up paying Apple. Could this mean a new deal for another cell phone producer? Maybe. More importantly, what does this mean for Verizon Wireless (VZ) and Apple (AAPL) shareholders? Read the article HERE to find out.

Sectors to Invest in Now!

Courtesy of My Fox 8 (website) via Google Images.
Courtesy of My Fox 8 (website) via Google Images.

Using relative performance analyses, Forbes contributor, Tom Aspray, identifies sectors that are leading the stock market higher. This type of analysis focuses on stocks that are outperforming the overall Dow Jones. Aspray goes on to discuss a variety of sectors that have outperformed and underperformed in the market during the last month. Check out the full article HERE to see which sectors and ETFs he advises investing in.



Will Gold Fall Again?

Courtesy of via Google Images.
Courtesy of via Google Images.

Looking at the price of gold in the long-term, it could fall below $800 an ounce. Though the nominal (real) price of gold has remained roughly the same, Duke University’s Fuqua School of Business professor, Campbell Harvey, said that gold is currently above its mean price. He went on to say that gold historically rises above the mean and falls below it. Read the article HERE to find out Harvey’s advice on what aspect of gold to invest in.

How to Efficiently Diversify Your Money

Courtesy of via Google Images.
Courtesy of via Google Images.

For long-term investment success, defining and maintaining your asset allocation is key. Diversification of funds into stocks, bonds, and other investments allows an appropriate level of risk for you as an investor while also ensuring that you’re not putting all your eggs in one basket. For instance, overconcentration in a single stock is something to watch out for because not all sectors prosper at the same time, which in turn can reduce portfolio risk. When selecting bonds, remember to look at styles, maturities, and sensitivity to inflation in order to understand how they will fit into your collection of assets. For more information on how to diversify your portfolio and strategies, read the full article HERE.

How Much Do You Need To Retire?

Is Your Retirement Money Safe?

120x60Discover how Annuities can guarantee monthly income for life and protect your retirement savings from market risk with returns up to 6.5%. Get the FREE Safe Money Guide plus annuity quotes from A-rated companies from See why 1000’s of people have turned to for their retirement needs. Get started today!

Access HERE

A Pharma You WON’T Want To Miss!

One successful or lackluster drug can make or break small and mid-sized pharmaceutical ventures. Savvy development strategies and an efficient pipeline are a must in this competitive sector.

Ironwood Pharmaceutical has used their industry knowledge to build partnerships and develop drugs with a high probability for success. They accomplish this by concentrating on three simple drug development criteria.

  • They identify medical conditions where there is a significant unmet need for effective treatment solutions
  • They target disorders that are highly symptomatic
  • They develop pharmaceutical treatment solutions whose superior effectiveness can be easily demonstrated with solid clinical evidence



Ticker                                     IRWD

Industry                                  Medical Laboratories & Research

Recent Price                          $10.80

Market Cap                            $1.2 b

Shares Outstanding              107.4 m

Average Volume                    185,588

Dividend Yield                        N/A




In August 2012, Ironwood Pharmaceutical’s (IRWD) newest drug – LINZESS™ (Linaclotide) – received FDA approval, leading to an $85 million milestone payment from partner and pharmaceutical heavy hitter, Forest Laboratories (FRX).

LINZESS™ has shown considerable promise as an irritable bowel syndrome (IBS) treatment during clinical trials. It was first discovered by Ironwood scientists in 2003. They secured financial support and partnership for LINZESS™ development, production and distribution from Forest Laboratories beginning in 2007.

IRWD has been able to leverage this combined strength to increase the size, scope and speed of LINZESS™ development, with commercialization forecast to begin in December 2012.


IRWD’s most recent quarterly numbers were released on November 6, 2012.

The company reported revenue of $96.4 million in the quarter. Up from last year’s third quarter revenue of $12.2 million. This is an increase of 689.1%. Ironwood Pharmaceutical also reported a net income of approximately $47.6 million… a year-over-year increase from a net loss of $20.6 million.

As of September 30, 2012, the company reported $125.8 million in cash and $360,000 of long-term debt.



Trailing P/E                                       N/A

Price / Sales                                     7.5 x

Return on Assets                            -9.6 %

Insider ownership                             0.2 %

Short Ratio                                       22.2 x

Current Ratio                                    5.7 x

Total Debt To Equity                         0.4 x



On November 28, 2012, Ironwood announced the approval of Linaclotide in Europe, which will be branded under the name Constella®. European Commission approval makes Constella® the first and only EU approved drug for the symptomatic treatment of moderate to severe IBS-C.

Ironwood and partner Forest Laboratories forecasts the commercial launch of Constella® to occur in the first half of 2013.

According to statistics, 10% of the EU suffers from IBS. And approximately one third of those patients suffer from the IBS-C form. This means Constella® could potentially help treat the symptoms of 15 million IBS-C sufferers across the EU.



Bryan E. Roberts Ph.D. – Independent Chairman of the Board

Peter M. Hecht Ph.D. – CEO and Director

Mark G. Currie Ph.D. – Senior Vice President – Research and Development, Chief Scientific Officer

Michael J. Higgins – CFO, COO, Senior Vice President

Thomas A. McCourt – Senior Vice President – Marketing and Sales, Chief Commercial Officer








Chart Courtesy of


IRWD’s 52-week low was $10.02 and the 52-week high was $15.92.  Right now the stock is trading at $10.80.  The 50-day moving average is near $11.75 a share and the 200-day moving average is at $12.56.  The company has a market cap of $1.2 billion and 107.4 million shares outstanding.

Victory Resources’ (TSX : VR) Analysis of Core Samples to Determine Southward Expansion of Reforma Property Complete!

Victory Resources (TSX : VR) just published the Stage I geophysical results from a drilling project announced in May, 2011.  Core samples from four diamond drill holes south of the Reforma Mine were analyzed to determine the southward expansion of their Reforma property’s ore zone.  Victory Resources has managed to acquire the Reforma property, a once operating mine rich in Zinc, Silver, Lead and Copper with Gold credits.  At the time, it was one of Penoles’ richest operating mines. It was shut down in 1980 due to labor problems and metal prices.  The plan is to re-open the mine using modern mining technology.  What’s exciting is the potential of this company… and their mining project. And we think you’ll agree.

To see the results and read the entire press release click here.











Interested in gold stock analysis, gold mines, silver, stock picks, best stocks, best buy stocks, investment analysis, top 10 gold stock recommendations, hot stock picks, stock market, the stock market. Learn more from  Also learn about trading,stock,market,stocks,tips,investment,advice,picks,recommendations,ipo,options,finance,financial,analysis,Nasdaq,trader, stock quotes,stock tips,investment strategies Zenect, Zenect Wealth, Zenect Realty News, Zen Money News provides you with free stock quotes, hot stock tips, unbiased investment strategies and financial analysis for profitable investing.